Mirum Pharmaceuticals Reports Positive Phase 2b Data for Volixibat in PSC
Mirum Pharmaceuticals (NASDAQ:MIRM) reported positive results from its Phase 2b VISTAS study of volixibat in primary sclerosing cholangitis at the EASL International Liver Congress. The data showed rapid and sustained reductions in pruritus, supporting an NDA submission by H2 2026.
Tickers: $MIRM
Topics: biotech drug_development liver_disorders rare_diseases